HBsAg Loss/Seroconversion in Low Replicative Chronic Hepatitis B Virus(HBV) Infection Patients

HBsAg Loss/Seroconversion in Low Replicative Chronic HBV Infection Patients With Low Level HBsAg Treated With Peginterferon Alpha

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02908763

Enrollment

200

Registered

2016-09-21

Start date

2016-08-31

Completion date

2019-09-30

Last updated

2018-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Hepatitis B

Keywords

Chronic Hepatitis B, Peginterferon Alpha

Brief summary

HBsAg Loss/Seroconversion is uncommon in Low replicative chronic HBV infection patients. The purpose of this study is to investigate the ability of peginterferon alpha to achieve HBsAg loss/seroconversion therapy in Low replicative chronic HBV infection patients with Low Level HBsAg.

Detailed description

Low replicative chronic HBV infection patients with low Level HBsAg were enrolled in the out-patient department of 3rd Affiliated Hospital of Sun Yat-sen University. All of them were HBsAg positive and anti-HBs negative for more than 6 months with HBV DNA\<2000 IU/mL and HBsAg levels ≤1000 IU/mL. All patients did not have other liver diseases and contraindications for interferon therapy. After giving informed consent, patients were treated with weekly subcutaneous injections of alfa-2a 180 micrograms/week or peginterferon alfa-2b 80 micrograms/week. The use of other immune suppressive or regulatory drugs and other antiviral drugs was prohibited during the course of the study. In this study, treatment endpoint was HBsAg loss(\<0.05 IU/mL) and anti-HBs positive(\>10 milli-International unit(mIU)/mL) defined as seroconversion. Depending on the decline of HBsAg level, treatment was either continued for a prolonged period (no more than 96 weeks) until the endpoint was achieved, or terminated in case of nonresponse. Treatment was proceeded if HBsAg level continued to decline until HBsAg seroconversion was achieved and the anti-HBs level was above 200 mIU/ml. If the patients were not willing to extend treatment, the therapy was ended at the time of HBsAg loss, or stopped without further decline of HBsAg levels.

Interventions

DRUGpeginterferon alfa

peginterferon alfa-2a 180 micrograms/week or peginterferon alfa-2b 80 micrograms/week, for at most 96 weeks.

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

1. Hepatitis B surface antigen (HBsAg) positive and \<1000 IU/mL. 2. Hepatitis B surface antibody (HBsAb) negative. 3. Hepatitis B e antigen (HBeAg) negative. 4. Hepatitis B virus DNA \<2000 IU/mL. 5. Absence of previous antiviral therapy.

Exclusion criteria

1. Patients with active alcohol and/or drugs consumption. 2. Patients with liver cirrhosis, Hepatocellular Carcinoma or other malignancies. 3. Patients with other factors causing liver diseases. 4. Pregnant and lactating women. 5. Patients with concomitant HIV infection or congenital immune deficiency diseases. 6. Patients with diabetes, autoimmune diseases. 7. Patients with important organ dysfunctions. 8. Patients with mental illness. 9. Patients who receive antineoplastic or immunomodulatory therapy in the past 12 months. 10. Patients who can't come back to clinic for follow-up on schedule.

Design outcomes

Primary

Measure	Time frame	Description
HBsAg Clearance Rate	96 weeks	Percentage of Participants with HBsAg negative.

Secondary

Measure	Time frame	Description
HBsAg Seroconversion Rate	96 weeks	Percentage of Participants with HBsAg negative and anti-HBsAg positive

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026